Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start

Injectable cabotegravir and rilpivirine (CAB/RPV), administered bimonthly by a medical provider, is convenient and improves privacy and medication management. One year after approval, myriad implementation barriers threaten the access and sustainability of this life-saving innovation: (1) eligibilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinto, Rogério M., Hall, Evan, Tomlin, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951790/
https://www.ncbi.nlm.nih.gov/pubmed/36662654
http://dx.doi.org/10.1097/JNC.0000000000000386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951790/
https://www.ncbi.nlm.nih.gov/pubmed/36662654
http://dx.doi.org/10.1097/JNC.0000000000000386

Ejemplares similares